抗OX40单抗KHK4083治疗轻中度斑块状银屑病的I期随机研究
该首例人体I期研究评估了单次递增剂量KHK4083在轻中度斑块状银屑病患者中的安全性、耐受性、药代动力学和免疫原性。结果显示单次给药至10 mg/kg IV或1.0 mg/kg SC总体安全耐受,无剂量限制性不良事件,最高剂量组和SC组可见PASI和sPGA改善迹象。
要点
- KHK4083单次给药至10 mg/kg IV或1.0 mg/kg SC安全耐受,无严重不良事件。
- 最常见治疗相关不良事件为轻度或中度寒战(9.1%)和输注/注射部位反应(7.3%)。
- 最高IV剂量和1.0 mg/kg SC组可见PASI和sPGA改善迹象。
核心结论
- KHK4083单次给药至10 mg/kg IV或1.0 mg/kg SC在轻中度斑块状银屑病患者中总体安全耐受,无剂量限制性不良事件。
研究设计与样本
- Phase 1a为开放标签,两个队列各6例接受单次0.003和0.001 mg/kg IV。
- Phase 1b为多中心、随机、双盲、安慰剂对照、单次递增剂量设计,共7个队列,按3:1随机至KHK4083(n=6)或安慰剂(n=2)。
- Phase 1b IV剂量为0.03、0.1、0.3、1.0、3.0和10 mg/kg,另设1.0 mg/kg SC。
- 共55例患者接受KHK4083。
主要发现
- 无严重或重度不良事件,无因不良事件停药。
- 55例接受KHK4083患者中最常见治疗相关不良事件为轻度或中度寒战(9.1%)和输注/注射部位反应(7.3%)。
- 实验室值、生命体征、心电图和体格检查未见有临床意义或剂量相关的变化。
- 54例中有10例治疗后产生抗KHK4083抗体。
- 平均消除半衰期随剂量增加,最大血清浓度呈剂量比例增加,IV给药AUC随剂量增加呈超剂量比例增加;SC绝对生物利用度为73%。
关键数值与推荐
- 最高IV剂量(1.0和10 mg/kg)和SC剂量(1.0 mg/kg)可见PASI和sPGA评分改善迹象。
- 最大PASI 50应答和sPGA评分改善≥2见于KHK4083 1.0 mg/kg SC。
临床怎么用
- KHK4083单次给药在轻中度斑块状银屑病中安全耐受,支持后续临床开发。
- 最高IV剂量和1.0 mg/kg SC的初步疗效信号需在更大样本中验证。
局限性
- 本研究为I期小样本研究,主要目的是安全性,疗效为探索性终点。
- 未报告P值或置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: OX40 (CD134) is expressed in lesional but not healthy skin of patients with psoriasis. KHK4083 is a fully human monoclonal antibody against OX40. OBJECTIVE: The primary aim of this first-in-human phase 1 study was to determine the safety and tolerability of ascending single doses of KHK4083 in patients with mild to moderate plaque psoriasis. Secondary aims were to determine the pharmacokinetics and immunogenicity of KHK4083, and an exploratory objective was to assess clinical activity. METHODS: In phase 1a, single doses of KHK4083 0.003 and 0.001 mg/kg IV were administered open label in two cohorts (each n = 6). Phase 1b had a multicentre, randomized, double-blind, placebo-controlled, ascending single-dose design in seven cohorts. Randomization was performed 3 : 1 to KHK4083 (n = 6) or placebo (n = 2) within each cohort. Ascending doses of KHK4083 were 0.03, 0.1, 0.3, 1.0, 3.0 and 10 mg/kg IV, and 1.0 mg/kg SC. RESULTS: There were no severe or serious adverse events (AEs), or discontinuations because of AEs. The most frequent treatment-related AEs in the 55 patients who received KHK4083 were mild or moderate chills (9.1%), and infusion/injection site reactions (7.3%). No clinically meaningful or dose-related changes from baseline in laboratory values, vital signs, ECG recordings or physical examinations were observed. Some KHK4083 recipients (10/54) developed anti-KHK4083 antibodies following treatment. Mean elimination half-life (t1/2 ) increased with dose, maximum serum concentration increased in a dose-proportional manner, and area under the serum concentration-time curve increased in a more than dose-proportional manner with increasing IV dose. Absolute bioavailability following SC administration was 73%. There was some indication of improvement in Psoriasis Area Severity Index (PASI) and sPGA scores at the highest IV doses (1.0 and 10 mg/kg) and the SC dose (1.0 mg/kg). The largest PASI 50 response and improvement in sPGA score ≥2 occurred with KHK4083 1.0 mg/kg SC. CONCLUSION: KHK4083 administration as a single dose up to 10 mg/kg IV or 1.0 mg/kg SC was generally safe and well tolerated in patients with mild to moderate plaque psoriasis with no dose-limiting AEs.
引用
- Papp KA, Gooderham MJ, Girard G, et al. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 2017. PMID: 28556418. doi:10.1111/jdv.14313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。